- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches 505(b)(2)
Drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications
Summer 2020
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Myfortic | Novartis | mycophenolic acid | Lupin | used for Prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant | 4/6/2020 |
Evekeo | Arbor | amphetamine | Dr. Reddy's | used to treat narcolepsy, attention deficit disorder with hyperactivity as an integral part of a total treatment program and exogenous obesity as a short term adjunct in a regimen of weight reduction | 4/14/2020 |
NitroDur | US Pharma | nitroglycerin | Dr. Reddy's | used to prevent angina pectoris due to coronary artery disease | 4/14/2020 |
Istodax | Celgene | romidepsin | Teva | used to treat peripheral T-cell lymphoma and cutaneous T-cell lymphoma in patients that the cancer comes back or does not respond to other cancer treatment | 4/16/2020 |
Tricor | AbbVie | fenofibrate | Dr. Reddy's | used to treat high cholesterol and triglycerides (fatty acids) in the blood | 4/27/2020 |
Jadenu | Novartis | deferasirox | Teva | used to treat chronically elevated levels of iron in the blood caused by repeated blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older | 4/27/2020 |
Rapamune | Pfizer | sirolimus | Apotex | used to prevent rejection (anti-rejection medicine) in people 13 years of age and older who have received a kidney transplant | 4/29/2020 |
Buprenex | Indivior | buprenorphine | Hikma | used to manage pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate | 5/4/2020 |
DDAVPP | Ferring | desmopressin | Dr. Reddy's | used to control bleeding in people with mild hemophilia A. | 5/6/2020 |
Riomet | Sun | metformin | Saptalis | used as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus | 5/13/2020 |
Sabril | Lundbeck | vigabatrin | Teva | used to treat refractory complex partial seizures (CPS) as an adjunctive therapy in patients 10 years of age and older who have responded inadequately to several alternative treatments | 5/15/2020 |
Mycamine | Astellas | micafungin | Fresenius Kabi | used to treat candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation | 5/12/2020 |
Robinul | Hikma | glycopyrrolate | Apotex | used as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation and as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated |
5/20/2020 |
Apriso | Bausch & Lomb | mesalamine | Lupin | used to maintain remission of ulcerative colitis in patients 18 years of age and older | 5/19/2020 |
Bentyl | Allergan | dicyclomine HCl | Hikma | used to treat irritable bowel syndrome | 5/28/2020 |
Coreg CR | GlaxoSmithKline | carvedilol | Apotex | used to treat high blood pressure; left ventricular dysfunction; heart failure; angina and belongs to the drug class non-cardioselective beta blockers | 6/1/2020 |
Migranal | Bausch & Lomb | dihydroergotamine mesylate | Custopharm | used to treat a migraine or cluster headache attack | 6/10/2020 |
Afinitor | Novartis | everolimus | Mylan | used to treat advanced hormone receptor-positive, HER2-negative breast cancer, along with the medicine exemestane, in postmenopausal women who have already received certain other medicines for their cancer; used to treat adults with advanced kidney cancer (renal cell carcinoma or RCC) when certain other medicines have not worked; used to treat adults with a type of pancreatic cancer known as pancreatic euroendocrine tumor (PNET) that has progressed and cannot be treated with surgery; used to treat adults with a type of cancer known as neuroendocrine tumor (NET) of the stomach and intestine (gastrointestinal) or lung that has progressed and cannot be treated with surgery; used to treat adults with a kidney tumor called angiomyolipoma, seen with a genetic condition called tuberous sclerosis complex (TSC), when their kidney tumor does not require surgery right away; used to treat adults and children with a genetic condition called tuberous sclerosis complex (TSC) who have a brain tumor called subependymal giant cell astrocytoma (SEGA) when the tumor cannot be removed completely by surgery. | 6/10/2020 |
Afinitor | Novartis | everolimus | Hikma | used to treat advanced hormone receptor-positive, HER2-negative breast cancer, along with the medicine exemestane, in postmenopausal women who have already received certain other medicines for their cancer; used to treat adults with advanced kidney cancer (renal cell carcinoma or RCC) when certain other medicines have not worked; used to treat adults with a type of pancreatic cancer known as pancreatic euroendocrine tumor (PNET) that has progressed and cannot be treated with surgery; used to treat adults with a type of cancer known as neuroendocrine tumor (NET) of the stomach and intestine (gastrointestinal) or lung that has progressed and cannot be treated with surgery; used to treat adults with a kidney tumor called angiomyolipoma, seen with a genetic condition called tuberous sclerosis complex (TSC), when their kidney tumor does not require surgery right away; used to treat adults and children with a genetic condition called tuberous sclerosis complex (TSC) who have a brain tumor called subependymal giant cell astrocytoma (SEGA) when the tumor cannot be removed completely by surgery. | 6/11/2020 |
Colcrys | Takeda | colchicine | Dr. Reddy's | used to treat gout flares in adults and Familial Mediterranean fever (FMF) in adults and children 4 years or older |
6/12/2020 |
Zytiga | J&J | abiraterone | Dr. Reddy's | used to treat men with prostate cancer that has spread to other parts of the body | 6/19/2020 |
GENERICally Speaking Summer 2020
Related Professionals
Christopher A. Pinahs
Partner
GENERICally Speaking Summer 2020
VOL. 10, NO. 2 Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.